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to optimize the managed entry of new drugs in the future through an 
iterative process. This includes guidance for all key groups on future 
activities to achieve this.
Results: There have been multiple demand-side activities among 
countries to manage the utilization of dabigatran. This included 
extensive prelaunch activities, risk-sharing arrangements, prescribing 
restrictions, and monitoring of prescribing postlaunch against agreed 
guidance. Clinical pharmacologists played a key role in a number 
of countries. Reimbursement was denied in some countries due to 
concerns with its budget impact and/or issues with excessive bleed-
ing. Development of a new model and future guidance was proposed 
to better manage the entry of new drugs in the future, centring on 
3 pillars of pre-, peri-, and postlaunch activities. This was accom-
panied by guidance to all key stakeholder groups, including health 
authorities, physicians, patients, and pharmaceutical companies on 
suggested activities pre- to postlaunch to reduce the likelihood of new 
drugs being withdrawn as well as enhance their chances of funding. 
This included guidance on key considerations that authorities should 
consider when evaluating risk-sharing arrangements or developing 
patient registries.
Conclusion: Models for introducing new drugs are essential to 
optimize their prescribing especially where there are concerns. As a 
result, promote high prescribing standards postlaunch. Without such 
models, new drugs may be withdrawn prematurely and/ or struggle 
for funding.
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Introduction: The sustained increase of cardiovascular disease in 
the developing world is a truly challenge. While > 80% of all CVD 
deaths occur in developing countries, the lack of longitudinal stud-
ies hinders the extrapolation of international recommendations for 
CVD prevention to a given country in the absence of risk predictors 
developed from local epidemiologic data. A risk estimation system 
has been developed by adapting the Framingham equations published 
in 1998 using local information to predict overall CHD risk in the 
Chilean population assuming a constant odds ratio for the risk fac-
tors between populations. The predictive power of the Chilean risk 
estimator has not been assessed. We explored the validity of predic-
tion by the Chilean risk equations against the CHD events observed 
in the Chilean population.
Patients (or Materials) and Methods: We performed a simula-
tion study to compare the predicted events in a Realistic Virtual 
Population (RVP) to the events observed in the Chilean population 
over 10 years. The RVP represents 10% of Chilean adults aged 35 to 
79 years with the CVD risk profiles reported by the National Health 
Survey of 2003. We derived the 10-year rates of CHD fatal and 
nonfatal from the individual risks by age and gender categories. We 
obtained the 10-year rates observed by extrapolating the latest annual 
incidence rates of fatal CHD and hospital discharges after nonfa-
tal CHD from national statistics using the life tables method. We 
performed predicted-observed comparisons for the Chilean-adapted 
Framingham equations, the Framingham equations developed by 
Anderson et al, and the SCORE equations estimates.
Results: The overall CHD events were overestimated by the Chilean 
risk equations in men and women < 55 years and underestimated 
in individuals of both genders older than 55 years. The calibration 
defaults were greater in women compared with men in all age catego-
ries. The overestimation of CHD with the Framingham model used as 
a reference was maximal in the second age category for both genders. 
The CHD fatal events were underestimated by SCORE in men and 
women at all ages although the age-related risk gradient was closer 
to the observed gradient compared with Framingham’s predictions.
Conclusion: The contribution of risk factors to CHD risk appears to 
be different in the Chilean population compared with the US popu-
lation. Overall, SCORE showed improved performance to predict 
Chilean CHD deaths.
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Introduction: Arterial hypertension represents a major cause of car-
diovascular morbidity and mortality in the city of Novi Sad, Serbia, 
with every fourth adult inhabitant suffering from it. The aim of this 
study was to analyze patterns of antihypertensives usage within 
different age groups of patients (30–40, 50–60, 70–80 years) and 
between genders.
Patients (or Materials) and Methods: The study was conducted in 
Novi Sad (estimated population 350,000) from September 2011 to 
February 2012. The data about antihypertensives issued on pre-
scription were collected from state-owned pharmacies in Novi Sad. 
Consumption was calculated using the ATC/DDD methodology, and 
results were expressed in DDD/1000 inhabitants/d.
Results: The total use of antihypertensives issued on prescription 
in Novi Sad was 282.6 DDD/1000 inhabitants/d. ACE inhibitors 
were the most frequently used antihypertensives in all age groups. 
Higher usage of beta-blockers in age group 30 to 40 years compared 
with other age groups was shown. Diuretics and calcium antagonists 
were more frequently prescribed to patients in age groups 50 to 60 
and 70 to 80. Most commonly prescribed antihypertensive drug in 
age group 30 to 40 was enalapril, in contrast to amlodipin, the most 
commonly prescribed antihypertensive in age groups 50 to 60 and 
70 to 80. The consumption of angiotensin receptor antagonists was 
low (< 3%) within all age groups.Women accounted for 59.9% of 
total consumption of antihypertensives. Only in age group of 30 to 
40 years, more antihypertensives were prescribed to men (62.9%) 
while in the age groups 50–60 and 70–80, the usage of antihyper-
tensives was significantly higher in women. Beta-blockers were more 
commonly used in women than in men, while for other groups of 
antihypertensives, no difference in usage was observed between male 
and female patients.
Conclusion: Widespread usage of ACE inhibitors, and low usage of 
other antihypertensives, especially diuretics, points to therapeutic 
irrationalities. The most cost-effective drugs – diuretics - accounted 
for only 4% of total consumption. High usage of more expensive 
antihypertensive agents presents a financial challenge for health care 
system.
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